Cellectis S.A. American Depositary Shares (CLLS) — Analysis Summary
Cellectis S.A. American Depositary Shares (CLLS) has a market cap of $357.99M with year-over-year revenue growth of +75.8%. Net margin stands at -92.7%. The stock trades at a P/E ratio of -5.3.
Key Takeaways
- Revenue changed +75.8% year-over-year
- Net margin of -92.7%
- P/E ratio of -5.3
Compared with its sector, CLLS posted revenue growth of +75.8% and trades at a P/E of -5.3.
Cellectis S.A. American Depositary Shares (CLLS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -0.6x — earnings do not cover interest payments
Current ratio at 0.00x — severe short-term liquidity risk
Operating margin at -45.3% — material operating losses
Net margin at -92.7% — significant losses
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Employees
229
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.